AFLAC Incorporated (AFL) Stock Price & How to Invest

Aflac Incorporated, headquartered in Columbus, Georgia, is the largest provider of supplemental health insurance sold at the worksite in the United States and the leading writer of cancer and medical insurance in Japan. The products are narrow by design: cash-benefit policies that pay the policyholder directly when a covered event happens (a cancer diagnosis, a hospital stay, an accident), sitting alongside rather than replacing major medical coverage. Aflac Japan, distributed through banks, independent agencies and the Japan Post network, is the larger of the two segments and produced pretax adjusted earnings of ~$759 million in Q1 2026 against ~$363 million for Aflac US. Because premiums are small, recurring and paid by payroll deduction or bank draft, the revenue base is unusually stable compared with property, casualty or annuity writers.

The investment picture is defined by three things that have little to do with insurance underwriting in the usual sense. First, roughly half to two-thirds of profit is earned in yen, so reported dollar results move with the currency even when the Japanese business is performing well. Second, the Japanese block is mature: net earned premiums there fell ~6.4% year over year in Q1 2026 as older policies reach paid-up status, which management is trying to offset with new third-sector products aimed at younger buyers (the Miraito cancer product and Tsumitasu medical launches drove a large sales increase). Third, the company converts that mature block into shareholder returns aggressively, returning ~$1.3 billion in Q1 2026 alone (~$1.0 billion of buybacks and ~$315 million of dividends), which shrinks the share count enough that per-share earnings can grow while total revenue does not. Total revenues were ~$17.2 billion in 2025, down ~9.3% from 2024, while adjusted earnings per diluted share rose to ~$7.49 from ~$7.21. That gap between falling revenue and rising per-share earnings is the whole story in one line.

The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. The second is demographic and structural, because Japan's population is aging and shrinking, the existing cancer and medical block keeps rolling into paid-up status, and net earned premiums there have been declining year over year. A third is that the company faces litigation exposure, including class actions stemming from the June 2025 cyberattack on its network that exposed customer data, plus longstanding disputes with sales associates over classification and sales practices. Interest rate volatility affects both investment income and the valuation of a large fixed-income portfolio, and a sharp move in Japanese government bond yields would hit the Japan investment book directly. Finally, the valuation carries little margin for disappointment: at roughly 14 times trailing earnings and about 2.1 times stated book value, with a modest dividend yield near 2%, most of the return has to come from execution on Japan sales and the buyback rather than multiple expansion.

14 analysts publish price targets on AFL, averaging $117.71 against a $125.56 price as of August 2026, or -6.3%. The published targets run from $98.00 to $137.00, a moderate spread, and the ratings split 3 buy, 8 hold, 3 sell. Over the last six months there have been 9 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AFL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on AFLAC Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Japan third-sector product refresh. Aflac Japan is trying to replace a shrinking in-force block with new sales to younger policyholders, and the Miraito cancer product plus the Tsumitasu medical launch drove a sales increase above 20% in recent quarters. The most optimistic published target, $137.00, assumes this works close to its best case.

The case against. The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. The most pessimistic target, $98.00, is roughly what AFL is worth if this bites instead.

Read the full bull and bear case on AFL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AFLAC Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$18.2 billion (FY2025 was ~$17.2 billion, down ~9.3% year over year)
• Net Earnings (TTM): ~$4.6 billion; Q1 2026 net earnings were ~$1.0 billion, or ~$1.98 per diluted share
• Adjusted EPS: ~$7.49 for FY2025; Q1 2026 adjusted EPS was ~$1.75, up ~5.4% year over year
• Market Cap / P/E (TTM): ~$63 billion at a share price near ~$124, or roughly ~14x trailing earnings of ~$8.75 per share
• Dividend: ~$2.44 per share annualized (~2.0% yield) after a 5.2% increase, marking 43 consecutive years of increases
• Book Value / ROE: Shareholders' equity of ~$30.0 billion (~$58.69 per share), with adjusted ROE excluding currency remeasurement of ~16.4%

Aflac's reported revenue line is noisier than the underlying business because it absorbs net investment gains and losses and yen translation, which is why 2025 revenue fell while adjusted earnings per share rose. The market has generally valued the stock in the low-to-mid teens on earnings, a discount to the broad market that reflects the shrinking Japanese premium base and the currency exposure, offset by high margins and heavy buybacks. Q2 2026 results were scheduled for release after the close on August 6, 2026, with consensus near ~$1.77 in adjusted EPS on ~$4.19 billion of revenue.

Other names that sit close to AFL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AFL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AFL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AFL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Aflac is a capital-return story built on high-margin supplemental insurance, where the return depends far more on Japanese policy sales, the yen and the pace of share repurchase than on anything happening in the US economy.

Whether AFL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AFL a buy or a sell?, and where the stock could go from here in the AFL stock forecast.

For income investors, whether AFL pays a dividend and how the payout looks is covered in does AFL pay a dividend? And to weigh AFL against a peer, read the full side-by-side comparisons: AFL vs UNM and AFL vs MET.